Trade

Laurus Labs share price

Balanced risk
  • 43%Low risk
  • 43%Moderate risk
  • 43%Balanced risk
  • 43%High risk
  • 43%Extreme risk
  • 827.15(0.68%)
    July 18, 2025 15:29:56 PM IST
    • NSE
    • BSE
  • Vol : 1.05M (NSE + BSE)
    Last 20 day avg : 2.59 M

Laurus Labs is trading 0.68% upper at Rs 827.15 as compared to its last closing price. Laurus Labs has been trading in the price range of 829.95 & 814.80. Laurus Labs has given 36.30% in this year & 3.53% in the last 5 days. Laurus Labs has TTM P/E ratio 92.17 as compared to the sector P/E of 25.87.There are 11 analysts who have initiated coverage on Laurus Labs. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 233.67 Crores in its last quarter.Listed peers of Laurus Labs include Glenmark Pharmaceuticals (-0.16%), Biocon (0.52%), Laurus Labs (0.68%).The Mutual Fund holding in Laurus Labs was at 6.88% in 31 Mar 2025. The MF holding has decreased from the last quarter. The FII holding in Laurus Labs was at 25.51% in 31 Mar 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Key Metrics

Updated on Jul 19, 2025, 12:09 AM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.15
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    9.36
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    116.85
    Higher than historical values
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.81
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.62
    Higher than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
814.80
Highest
829.95
52 week range
Lowest
390.30
Highest
834.45
Laurus Labs Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in March quarter by 19.49% from Rs 1720.30 crore to Rs 1439.67 crore, year-on-year
    • financial-insightsThe company has grown its March quarter profit by 209.05% from Rs 75.61 crore to Rs 233.67 crore, year-on-year
    • financial-insightsThe debt to equity of the company is higher than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Laurus Labs Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 804.80
  • R2
  • 884.70
  • R3
  • 934.95
Pivot754.55
  • S1
  • 674.65
  • S2
  • 624.40
  • S3
  • 544.50
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Laurus Labs Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Glenmark Pharmaceuticals
Bullish
2,223.05-0.1662,734.6537.955.690.147.90
Biocon
Bullish
398.900.5253,365.1047.702.080.1359.81
Laurus Labs
Bullish
827.150.6844,630.49129.299.150.1615.82
Suven Pharmaceuticals
Neutral
1,071.50-1.9740,005.7096.4015.12-10.36
Ipca Laboratories
Moderately Bullish
1,472.00-0.1537,297.8640.795.170.288.55
Laurus Labs Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Laurus Labs is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPledged found - Promoter(s) have pledged 2.69% of shares.
    • InsightsPledging Flat - Promoter(s) pledging has not increased in last quarter.
    • InsightsPromoter(s) does not have a high stake in the company
    • InsightsPromoter(s) have increased the stake in the company in last 12 months
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has decreased by 0.05 percentage points from previous quarter
    • InsightsMutual Funds holding has decreased by 0.74 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    DSP Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 135.21
    • % of AUM 4.57
    Tata Nifty MidSmall Healthcare Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 5.87
    • % of AUM 4.30
    Motilal Oswal Nifty MidSmall Healthcare Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 1.04
    • % of AUM 4.28
    Kotak Nifty Smallcap 50 Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 4.71
    • % of AUM 3.63
    Aditya Birla Sun Life Nifty Smallcap 50 Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 8.38
    • % of AUM 3.63
    Laurus Labs Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-07-25Quarterly Results
    2025-04-24Audited Results & Interim Dividend
    2025-01-24Quarterly Results
    2024-10-24Quarterly Results & Interim Dividend
    2024-07-25Quarterly Results
    About the company Laurus Labs
    • IndustryBiotechnology & Drugs
    • ISININE947Q01028
    • BSE Code540222
    • NSE CodeLAURUSLABS
    Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers an integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. It operates through four divisions: Generics API, Generics FDF, CDMO custom synthesis (Laurus Synthesis), and Biotechnology (Laurus Bio). The Generics API is a third-party API supplier for antiretrovirals. The Generic FDF business focuses on oral solid formulations. Laurus Synthesis provides drug development and manufacturing services to global pharma, crop science, animal health, and others. Laurus Bio offers comprehensive services from clone and strain engineering to production, supporting clients across the microbial precision fermentation spectrum. Its solutions cater for sectors, such as regenerative medicine, vaccines, cultured meat, and others.
    • Management Info
    • Satyanarayana ChavaChief Executive Officer, Executive Director
    • Venkata Ravi VantaramChief Financial Officer, Executive Director
    • V. Uma Maheswer RaoPresident Chemical R and D
    • Srinivasa SuryadevaraPresident - Manufacturing and Operations
    • Thomas VersoskyPresident - FDF, North America
    • Jyothi Basu AbbibeniExecutive Vice President - Chemical R and D
    • Narasimha ChavaExecutive Vice President - Human Resources
    • Rajaram IyerExecutive Vice President Portfolio Management
    • Martyn James PeckExecutive Vice President Business Development
    • Sita RamaiahExecutive Vice President - Finance
    Laurus Labs Share Price FAQs

    Laurus Labs is trading at 827.15 as on Fri Jul 18 2025 09:59:56. This is 0.68% upper as compared to its previous closing price of 821.55.

    The market capitalization of Laurus Labs is 44630.49 Cr as on Fri Jul 18 2025 09:59:56.

    The 52 wk high for Laurus Labs is 834.45 whereas the 52 wk low is 390.30

    Laurus Labs can be analyzed on the following key metrics -

    • TTM P/E: 92.17
    • Sector P/E: 25.87
    • Dividend Yield: 0.15%
    • D/E ratio: 0.62

    Laurus Labs reported a net profit of 358.32 Cr in 2025.

    The Mutual Fund Shareholding was 6.88% at the end of 31 Mar 2025.